Pharmacokinetic profile of SKP-1041, a modified release formulation of zaleplon.

OBJECTIVES: Two investigations aimed to define the pharmacokinetic profile of a modified-release preparation of zaleplon (SKP-1041). METHODS: Protocol SOM001 was a 5-way crossover, double-blind, randomized trial comparing three novel modified-release formulations of zaleplon 15 mg (SKP-1041A, SKP-1041B, SKP-1041C) to placebo and immediate-release zaleplon 10 mg. Protocol SOM002 was a randomized, crossover, open-label trial to compare the pharmacokinetics of SKP-1041B after day and night administration. In SOM001, study drug was administered at 9:00 a.m. (fasted); blood samples were obtained beginning 1 h predose through 12 h postdose. In study SOM002, study drug was administered at 9:00 a.m. or 10:30 p.m.; blood samples were obtained beginning 1 h predose through 12 h postdose. Subjects were 19 (SOM001) and 23 (SOM002) healthy adults between ages 20-46. RESULTS: Dose-normalized total AUCs for modified-release preparations A, B, C and immediate-release zaleplon were not significantly different; peak plasma concentrations were similar for A and B, and both were significantly higher than C. Time to peak plasma concentration for A, B, and C were 4-5 h compared to 1.5 h for immediate-release zaleplon; mean terminal phase half-life was in the range 1-2 h for A, B and immediate-release zaleplon. No significant differences were noted between day and night administration in the SOM002 study. CONCLUSIONS: Zaleplon, 15 mg, in a novel, modified-release formulation (SKP-1041) had a time to peak plasma concentrations at 4-5 h postdose compared to 1.5 h for immediate-release zaleplon, 10 mg. The pharmacokinetic profile suggests this formulation may be useful for treating middle-of-the-night awakening.

Texture analysis of the brain: from animal models to human applications.

Magnetic resonance imaging (MRI) is widely used to image brain in vivo both in studies in animal models and for human diagnosis. A large part of the value of MRI is due to the fact that soft tissue contrast is enhanced by the substantial variation in the T(1) and T(2) relaxation times between tissues. It may be possible to use an alternative approach, which does not rely on the absolute measurement of relaxation times. Generally speaking, textures are complex visual patterns composed of entities, or subpatterns, that have characteristic brightness, color, slope, size, etc. Thus, texture can be regarded as a similarity grouping in an image. The properties of the local subpattern give rise to the perceived lightness, uniformity, density, roughness, regularity, linearity, frequency, phase, directionality, coarseness, randomness, fineness, smoothness, and granulation. The purpose here is to illustrate how texture analysis can be used in animal models and in human clinical applications, as well as in the search for further pharmacological applications in humans. Thus, this article summarzes three different MRI studies in (i) rats, using the lipocarpine epileptic rat model as an animal model; (ii) patients with Alzheimer's disease; and (iii) patients with schizophrenia.

Multinuclear NMR investigations on the metabolic recovery of the isolated perfused mouse liver after cold preservation.

This paper describes multinuclear NMR investigations on the isolated perfused mouse liver to optimize its recovery after cold preservation and normothermic reperfusion. The recovery of livers from fed is better than that from 24 h fasted animals. This better recovery is not due to a higher glycogen content before cold preservation. The recovery of livers from fasted animals is specifically enhanced by the presence of 8 mM alanine in the rinsing solution after cold preservation and in the perfusate of reperfusion. This property is not due to the ability of alanine to compensate for the lack of endogenous substrates since the amount, before cold preservation, of these substrates, is not significantly different in livers from fed and fasted animals. Furthermore, the beneficial effect of alanine is not due to an enhancement of the pyruvate dehydrogenase (PDH) activity in livers from fasted animals. In fact these livers have indeed a smaller PDH activity than the livers from fed animals but dichloroacetate, a known PDH activator has a rather deleterious effect on the recovery of fed and fasted livers. Furthermore alanine protects the fasted livers against this effect. So the beneficial effect of alanine should be due to other causes. Furthermore, we have found on a parallel model of rat isolated perfused liver, that the recovery of steatotic livers which is lower than that of normal fed livers is enhanced by a known vasodilator, pentoxifylin but not by alanine. So alanine does not either play its role through its action on microcirculation. The interaction of alanine with some membrane sodium transporters like that already reported for another protective aminoacid, glycine, is thus possible. A novel NMR method of (23)Na observation in living cells or organs should be of great interest to investigate this hypothesis.

Localized 2D correlation spectroscopy in human brain at 3 T.

The purpose of this study was to acquire a localized 2D (two-dimensional) 1H correlation spectrum, in a volume of interest reasonably small, and within an experiment time compatible with clinical applications. A modified PRESS technique has been used. The last 180 degrees pulse of the PRESS sequence has been converted into a 90 degrees pulse for both refocusing and coherence transfer. 2D correlation spectroscopy was performed on healthy volunteers in a clinical magnet, at 3 T, within 34 min, for a voxel size of 27 cm3. This result makes it possible to consider clinical applications.

Human models as tools in the development of psychotropic drugs.

Despite the growing means devoted to research and development (R α D) and refinements in the preclinical stages, the efficiency of central nervous system (CMS) drug development is disappointing. Many drugs reach patient studies with an erroneous therapeutic indication andlor in incorrect doses. Apart from the first clinical studies, which are conducted in healthy volunteers and focus only on safety, iolerability, and pharmacokinetics, drug development mostly relies on patient studies. Psychiatric disorders are characterized by heterogeneity and a high rate of comorbidity. It is becoming increasingly difficult to recruit patients for clinical trials and there are many confounding factors in this population, for example, those related to treatments. In order to keep patient exposure and financial expenditure to a minimum, it is important to avoid ill-designed and inconclusive studies. This risk could be minimized by gathering pharmacodynamic data earlier in development and considering that the goal of a phase 1 plan is to reach patient studies with clear ideas about the compound's pharmacodynamic profile, its efficacy in the putative indication (proof of concept), and pharmacokinetic/pharmacodynamic relationships, in addition to safety, tolerability, and pharmacokinetics. Human models in healthy volunteers may be useful tools for this purpose, but their use necessitates a global adaptation of the phase scheme, favoring pharmacodynamic assessments without neglecting safety. We are engaged in an R α D program aimed to adapt existing models and develop new paradigms suitable for early proof of concept substantiation.